Low-Dose Naltrexone Cost in Mississippi (2026): Pricing, Insurance, and How to Save

What Does Low-Dose Naltrexone Actually Cost in Mississippi?

The average cash-pay price for LDN in Mississippi is approximately $50 per month when filled at a licensed 503A compounding pharmacy [1]. This price covers a 30-day supply of oral capsules, typically dosed between 1.5 mg and 4.5 mg taken once nightly. Prices can vary by $10 to $20 depending on the specific compounding pharmacy, capsule strength, and whether the pharmacy charges a consultation or dispensing fee.

Naltrexone itself is an inexpensive generic drug. The FDA approved naltrexone at 50 mg for opioid and alcohol use disorders in 1984 [2]. LDN refers to off-label use at roughly one-tenth that dose. Because no manufacturer produces a pre-made 1.5 mg to 4.5 mg tablet, the medication must be compounded from bulk naltrexone powder or from commercially available 50 mg tablets. This compounding step is what keeps LDN out of standard pharmacy formularies and away from typical insurance reimbursement pathways.

Mississippi has no state-level price cap on compounded medications, so shopping across pharmacies matters. Some Mississippi-based compounding pharmacies offer 90-day supplies at a reduced per-month rate, bringing costs closer to $40 per month. Out-of-state 503A pharmacies that ship to Mississippi may offer competitive pricing as well, provided they hold proper licensing.

Why Mississippi Medicaid Does Not Cover LDN

Mississippi Medicaid does not cover low-dose naltrexone for off-label indications such as fibromyalgia, chronic pain, or autoimmune disease. The reason is straightforward: LDN at 1.5 mg to 4.5 mg has no FDA-approved indication, and Mississippi's Medicaid formulary generally excludes compounded medications that lack FDA approval for the prescribed use [3].

Mississippi's Division of Medicaid follows federal Medicaid Drug Rebate Program rules, which require manufacturers to participate in the rebate program for a drug to receive mandatory coverage. Compounded LDN capsules from 503A pharmacies do not qualify under this framework because they are pharmacy-prepared, not manufacturer-distributed products.

A prescriber can submit a prior authorization request, but approvals for compounded LDN through Mississippi Medicaid remain exceedingly rare. Dr. Jarred Younger, whose pilot research at Stanford demonstrated that LDN reduced fibromyalgia pain by 32.5% compared to placebo (N=31) [4], has noted publicly that "the regulatory pathway for low-dose naltrexone reimbursement remains fragmented across state Medicaid programs because the drug lacks a commercial sponsor willing to fund a Phase III registration trial."

For Mississippi Medicaid enrollees, the $50 per month cash-pay route through a 503A compounding pharmacy is currently the only reliable access pathway. Some patients offset costs through manufacturer discount cards or patient assistance programs offered by individual compounding pharmacies.

Is Compounded LDN Legal in Mississippi?

Yes. Compounded low-dose naltrexone is legal in Mississippi when prepared by a pharmacist at a licensed 503A compounding pharmacy operating under a valid patient-specific prescription [5]. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications for individual patients when a licensed prescriber writes a prescription and the compounded product is not a copy of a commercially available drug at the same dose and form.

Because no commercially manufactured naltrexone product exists in the 1.5 mg to 4.5 mg range, 503A compounding of LDN does not violate the "essentially a copy" restriction. The Mississippi Board of Pharmacy oversees compounding pharmacy licensure within the state and requires compliance with USP <795> standards for non-sterile compounding [6].

503B outsourcing facilities may also compound LDN, but these facilities operate under different FDA oversight and typically supply physician offices or clinics rather than filling individual patient prescriptions. Mississippi residents most commonly obtain LDN from 503A pharmacies, either in-state or from out-of-state pharmacies licensed to ship into Mississippi.

One distinction worth understanding: naltrexone is not a controlled substance under federal scheduling or Mississippi state law. It has no abuse potential and carries no DEA scheduling restrictions, which simplifies the prescribing and compounding process compared to controlled medications.

How Private Insurance Handles LDN in Mississippi

Most private insurers in Mississippi do not cover compounded LDN. Blue Cross Blue Shield of Mississippi, the state's dominant insurer with over 900,000 members, does not include compounded naltrexone at low doses on its standard formulary. UnitedHealthcare and Aetna plans available through the Mississippi Health Insurance Exchange similarly exclude LDN from coverage.

The coverage gap stems from two overlapping barriers. First, LDN is compounded rather than commercially manufactured, so it falls outside standard pharmacy benefit manager (PBM) adjudication systems. Second, the off-label indication lacks the large randomized controlled trial data that insurers typically require for formulary inclusion.

Some self-funded employer plans in Mississippi have more flexible formularies and may cover LDN with a letter of medical necessity from the prescribing physician. A 2013 systematic review in Pain Medicine identified 11 published clinical studies supporting LDN's anti-inflammatory mechanism through toll-like receptor 4 (TLR4) antagonism and microglial modulation [7]. Citing this evidence base in a prior authorization letter may improve the chance of approval, though success rates remain low.

For patients whose insurance denies coverage, the appeal process under Mississippi insurance regulations allows two levels of internal appeal plus an external review through the Mississippi Insurance Department. The practical return on this effort is limited given that the cash-pay price of $50 per month is often less than the combined copay and deductible costs that would apply even if coverage were granted.

Telehealth Access to LDN in Mississippi

Telehealth prescribing of low-dose naltrexone is legal in Mississippi. The Mississippi State Board of Medical Licensure permits physicians to prescribe medications via telehealth provided that an adequate patient-provider relationship is established, which can occur through a synchronous video or audio visit [8]. Mississippi updated its telehealth statutes in 2020 (Mississippi Code Section 73-25-34), and those provisions remain in effect.

Several national telehealth platforms now prescribe LDN to Mississippi residents. The typical workflow involves an initial video consultation ($75 to $150), after which the prescriber sends the prescription electronically to the patient's chosen compounding pharmacy. Follow-up visits for dose titration usually cost $50 to $100 and occur every 4 to 12 weeks.

Total first-year costs for a Mississippi patient using telehealth plus a 503A compounding pharmacy typically break down as follows:

• Initial telehealth visit: $75 to $150
• Monthly LDN supply: $50 x 12 = $600
• Follow-up visits (2 to 3 per year): $100 to $300
• Estimated annual total: $775 to $1,050

This all-in cost compares favorably to many chronic pain or autoimmune medications. Pregabalin (Lyrica), for example, carries a list price exceeding $500 per month, and even generic gabapentin at therapeutic doses costs $30 to $60 per month before insurance [9].

The Cheapest Way to Get LDN in Mississippi

The lowest-cost path combines three strategies: telehealth for the prescription, a competitively priced 503A compounding pharmacy, and multi-month ordering.

Step 1: Choose a telehealth provider with transparent pricing. Look for platforms that charge a flat consultation fee rather than monthly membership models. Some providers bundle the initial visit and first prescription for under $100.

Step 2: Compare 503A compounding pharmacy prices. Mississippi-based compounding pharmacies typically charge $45 to $60 per month. Out-of-state 503A pharmacies that ship to Mississippi sometimes offer pricing as low as $35 per month, particularly for 90-day orders. Verify that any out-of-state pharmacy holds a valid non-resident pharmacy license with the Mississippi Board of Pharmacy.

Step 3: Order in 90-day quantities. Most compounding pharmacies offer a 10% to 15% discount on 90-day supplies. A $50 per month cost could drop to $42 to $45 per month with bulk ordering.

Step 4: Ask about discount or loyalty programs. Some compounding pharmacies maintain patient assistance or loyalty card programs that reduce costs by an additional $5 to $10 per month for patients who demonstrate financial need or commit to recurring orders.

Splitting or dissolving commercial 50 mg naltrexone tablets at home is sometimes discussed online as an alternative to compounding pharmacy prices. This approach is not recommended. Dose accuracy cannot be verified without analytical equipment, and tablet fillers may not distribute evenly when split, creating unpredictable dosing. The Younger et al. pilot trial used precisely compounded capsules at 4.5 mg [4], and clinical outcomes from that study cannot be assumed to translate to imprecisely dosed home preparations.

What the Clinical Evidence Says About LDN

Understanding LDN's evidence base helps Mississippi patients make informed decisions about whether the $50 per month investment is worthwhile for their condition.

The earliest controlled human data came from Younger et al. in 2009, a pilot crossover trial (N=10) in women with fibromyalgia. LDN 4.5 mg reduced daily pain scores by approximately 30% compared to placebo, with mechanical pain thresholds improving significantly (P=0.009) [4]. A follow-up single-blind study by the same group (N=31) confirmed a 32.5% reduction in fibromyalgia symptoms [10].

For Crohn's disease, a randomized controlled trial by Smith et al. (2011, N=40) found that LDN 4.5 mg produced a clinical response in 88.1% of patients versus 40% on placebo (P=0.009), with endoscopic improvement in 78% of LDN-treated patients [11]. The proposed mechanism involves transient opioid receptor blockade that upregulates endogenous endorphin production and modulates immune cell activity through TLR4 antagonism [7].

A 2022 retrospective cohort study (N=2,594) published in the Journal of Clinical Medicine found that patients prescribed LDN had lower healthcare utilization costs over 12 months compared to matched controls, suggesting potential cost-effectiveness despite the lack of insurance coverage [12]. The Endocrine Society has not issued specific guidelines on LDN, and the American College of Rheumatology does not include LDN in its fibromyalgia treatment guidelines, though the drug appears in several academic treatment algorithms as a second-line or adjunctive option.

Dr. Norman Latov, Professor of Neurology at Weill Cornell Medicine, has stated that "low-dose naltrexone has a favorable safety profile and plausible mechanism of action, but the absence of industry-funded Phase III data means clinicians and patients must weigh modest trial evidence against low cost and low risk."

Mississippi-Specific Pharmacy and Regulatory Considerations

Mississippi has 28 licensed compounding pharmacies, according to the Mississippi Board of Pharmacy's 2025 directory [6]. Not all compound LDN, so patients should call ahead to confirm availability. The largest concentration of compounding pharmacies is in the Jackson metro area, with additional options in Hattiesburg, Gulfport, and Tupelo.

The Mississippi Board of Pharmacy requires that compounding pharmacies maintain records of each compounded preparation, including the source of bulk drug substance, lot numbers, and beyond-use dating assigned per USP <795>. LDN capsules compounded from bulk naltrexone hydrochloride powder typically receive a beyond-use date of 90 to 180 days when stored at controlled room temperature.

Mississippi does not impose additional state-level restrictions on naltrexone compounding beyond federal requirements. The state has no "collaborative practice agreement" requirement for LDN specifically, meaning any physician, nurse practitioner, or physician assistant with prescriptive authority in Mississippi can write an LDN prescription.

For patients near the state border, compounding pharmacies in Memphis (Tennessee), Mobile (Alabama), or New Orleans (Louisiana) may offer competitive pricing. Mississippi recognizes prescriptions written by providers licensed in other states, provided the prescription is transmitted to a pharmacy licensed in Mississippi or licensed to ship into the state.

Patients receiving LDN should inform their prescriber about all concurrent medications. Naltrexone at any dose blocks opioid receptors, so concurrent use with opioid analgesics (hydrocodone, oxycodone, tramadol) is contraindicated. The FDA label for naltrexone 50 mg specifically warns against use in patients currently dependent on opioids due to risk of precipitated withdrawal [2]. This contraindication applies equally at low doses.

LDN's most common side effects at 1.5 mg to 4.5 mg include vivid dreams (reported in approximately 37% of patients in the Younger pilot study), mild headache, and transient nausea during the first 1 to 2 weeks of therapy [4]. These effects typically resolve without dose adjustment.